$32.570
-1.140 (-3.50%)收盘时
QNCX 同业对比
In the context of the broader market, QNCX competes directly with industry leaders such as QNTM and IGC. With a market capitalization of $34.33M, it holds a significant position in the sector. When comparing efficiency, QNCX's gross margin of N/A stands against QNTM's N/A and IGC's 18.11%. Such benchmarking helps identify whether Quince Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.
Quince Therapeutics Inc 财务表现
Quince has shown a significant turnaround with a net income of $35,912,000 in Q1 2026 after a series of losses, indicating potential recovery. The current ratio is strong at 14.52, suggesting good short-term financial health.
Financials
FY2026Q2
YoY:
+114.52%
-21.23M
Operating Profit
FY2026Q2
YoY:
+370.36%
-75.49M
Net Income after Tax
FY2026Q2
YoY:
-82.09%
-12.31
EPS - Diluted
FY2026Q2
YoY:
+63.65%
-18.89M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。